

PRESS RELEASE

October 13, 2008

iNovacia and AstraZeneca hereby announces the successful completion of a drug discovery project

The aim of the collaboration was discovery and generation of novel back-up chemotypes for an on-going project at AstraZeneca. The project included an advanced assay, screening of 100 000 compounds and chemistry – including the biophysical tools routinely applied at iNovacia in order to quickly rank and characterize hit series according to their attractiveness for further development.

The project was conducted as a close collaboration between the research units at AZ and iNovacia and completed successfully on time and within budget.

About iNovacia

iNovacia provides drug discovery services to translate targets into validated leads for biotech and pharmaceutical companies. Enabled by a strong chemical library, unique applications of biophysical tools, and long-standing experience in drug discovery, iNovacia develops hits, from both fragment-based screening and conventional HTS with the company's own libraries, or with those provided by a customer, into drug leads. iNovacia scientists are experts in optimizing the probability of success in development establishing a qualified early SAR/pharmacophore model.

Furthermore, iNovacia offers expertise in characterization and pre-formulation of protein pharmaceuticals and develops software for electronic capturing and analysis of experimental data to enhance research output. For more information see www.inovacia.se

For further information, please contact

iNovacia AB

Dr. Thomas Olin, CEO
Lindhagensgatan 133
SE-112 51 Stockholm, Sweden
olth@inovacia.se
+46 (0)8 50 10 30 40 Office
+46 735 20 40 01 Direct

Peter Halkjaer-Knudsen, Sr VP
Alliances and Business Development
Lindhagensgatan 133
SE-112 51 Stockholm, Sweden
hape@inovacia.se
+46 (0)8 50 10 30 40 Office
+46 735 20 40 35 Direct